Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of BIA 9-1067 (Opicapone) in Healthy Volunteers (Fasted vs Fed)
NCT02071823Phase 1Completed
- Sponsor
- BIAL
- Start
- May 2008
- Primary completion
- Jun 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of opicapone in Parkinson's disease (PD) (2 arms), sponsored by BIAL. Primary endpoints: Maximum Observed Plasma Concentration at Day 1, Cumulative Area Under the Plasma Concentration Time Curve at Day 1 and 1 more. Started May 2008; status: completed.
02
Drugs
opicapone
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT02071823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02071823.